Nebulizers Market: Information, Figures and Analytical Insights 2020-2027

 Global Nebulizers Market is expected to hold a value of USD 1,629.7 Million by 2027 and is expected to register a growth of 7.32% from 2020 to 2027.

Nebulizers Market Synopsis

Nebulizers are a device that has the capability of changing a medication from a liquid to a mist so that it can be inhaled into the lungs. High demand for respiratory devices, including nebulizers, due to the outbreak of COVID-19 globally, growing need for rescue medication, increasing prevalence of respiratory diseases, and rising demand for home healthcare devices are the key factors that are expected to drive the market growth. Moreover, the growing geriatric population, increasing consumption of alcohol, tobacco, cigarettes, and other such products may lead to respiratory diseases, and the rising number of initiatives taken by the government as well as the private organizations are also expected to boost the market growth.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/9586 

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas region held the largest market in 2019, owing to the rising demand for respiratory diseases in the region. The nebulizers market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European nebulizers market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The nebulizers market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the increasing incidence rate of respiratory diseases, the market in Asia-Pacific is expected to be the fastest-growing. The nebulizers market in the Middle East & Africa has been divided into the Middle East and Africa.

Segmentation

The Global Nebulizers Market has been Segmented Based on the Type, Usage, Portability, and End User.

Based on the Type, the global nebulizers market has been segmented into mesh, jet, and ultrasonic. The mesh segment is further divided into active and passive. The jet segment is expected to hold the largest market share owing to its low cost as compared to other types of nebulizers.

On the basis of usage, the market has been segmented into reusable and disposable. The disposable nebulizers are expected to hold a major market share owing to their growing popularity amongst the users.

Based on the portability, the market has been segmented into tabletop and portable. The portable nebulizers market is expected to grow at the fastest CAGR owing to its ease and convenience of use.

The market based on end-user has been segmented into hospitals & clinics, home care, and others. The hospitals and clinics segment is expected to hold the largest market share owing to the larger patient footfall in hospitals.

Key Players

Some of the key players in the global nebulizers market are OMRON Healthcare (Japan), Koninklijke Philips N.V. (Netherlands), PARI (US), Vectura Group plc (UK), Rossmax International Ltd (Taiwan), Briggs Healthcare (US), GF Health Products, Inc. (US), Beurer GmBH (Germany), Agilent Technologies, Inc. (US), Drive DeVilbiss Healthcare (US), Invacare Corporation (US), and B. Braun Melsungen AG (Germany).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/nebulizers-market-9586 

 

Impact of Existing and Emerging Global Influenza Vaccines Market Trends And Forecast 2020-2025

 Global Influenza Vaccines Market is expected to register a CAGR of 6.53% to reach USD 7,828.3 Million by 2025. Influenza viruses are one of the major infectious disease threats to the human population. Vaccination is the major public health measure for the prevention of influenza virus infection. Influenza vaccines are also known as flu shots or flu jabs. Currently available seasonal influenza vaccines are either trivalent or quadrivalent in composition.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1621 

Global Influenza Vaccination Market   - Competitive Analysis

Abbott (U.S.), AstraZeneca (Europe), BioCryst Pharmaceuticals, Inc. (U.S.), Novartis AG (Europe), DAIICHI SANKYO COMPANY, LIMITED. (Asia Pacific), GlaxoSmithKline plc. (Europe). Hualan Biological Engineering Inc (Asia Pacific), Mitsubishi Tanabe Pharma Corporation (Asia Pacific), F. Hoffmann-La Roche Ltd (Europe), Sanofi (Europe), Paxvax Corporation (U.S.) are some of the prominent players at the forefront of competition in the Global Influenza Vaccination Market and are profiled in MRFR Analysis. 

GSK plc. is a science-led global healthcare company that researches and develops a broad range of innovative products in three primary areas of pharmaceuticals, vaccines and consumer healthcare. As one of the few healthcare companies researching both medicines and vaccines for the World Health Organization’s three priority diseases – HIV/AIDS, tuberculosis and malaria, the company has developed some of the leading global medicines in these fields. GSK’s product portfolio also includes a range of consumer brands, many of which are household names around the world, including Sensodyne, Aquafresh, Horlicks, Panadol and Tums.

GSK plc. is headquartered ate Middlesex, United Kingdom. Geographically, the company operates in the regions like North America, South and Central America, Europe, Middle East, Asia, Africa and Australia. The company has a headcount of more than 10,000 employees all across world.

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Merial.

The company is also a P5 member (Pox-Protein-Public Private Partnership) for the development of the HIV vaccine candidate RV 144 that is in the III phase

Sanofi is headquartered in Paris, France. Geographically, the company operates in the regions like North America, South America, Europe and Asia-Pacific, Africa in more than 100 countries with the headcount of more than 10,000 employees.

Incorporated in 2007 and headquartered at California, United State; PaxVax is a biotechnology company that is dedicated in develops, manufactures and commercializes innovative specialty vaccines against infectious diseases; cholera (Vaxchora) & typhoid fever (Vivotif) and vaccines at various stages of research and clinical advancement for HIV, adenovirus, anthrax, hepatitis A, and zika. The company has its research and development centers in various countries like San Diego, California and Bern, Switzerland and other operations in Bermuda and Europe.

The company focuses mainly on delivering its HIV vaccine in various regions all around the world. The company has raised around $200 million from its investors including Cerberus Capital Management, Ignition Growth, Ignition Ventures and the Wellcome Trust. The company also has collaborations with various organizations for its research & development from the U.S. National Institutes of Health (NIH) and the Bill & Melinda Gates Foundation.

The company is specialized in various Viral Vaccines, Cholera, HIV, Adenovirus, Influenza, Vivotif oral typhoid vaccine.

Geographically, the company operates in various regions like San Diego, California Bern, Switzerland, United States, Europe and Bermudathe. As of now the company has a headcount of around 200 employees operating from various regions

Global Influenza Vaccination Market   - Regional Analysis

America dominates the global influenza vaccination market. Increasing prevalence of the influenza and high per capita healthcare expenditure are the major driver for the American influenza vaccination market. Moreover, the presence of developed economies like the U.S. and Canada and growing geriatric population within the regional boundaries of the Americas fuels the market growth. Europe holds the second market for influenza vaccination owing to the availability of funds for research and huge patient population. Moreover, global players like F. Hoffmann-La Roche Ltd and Novartis AG are present within the region which fuels the market growth. Asia Pacific is the fastest growing region for the market. Presence of developing economies like India and China and favourable government policies along with the growing geriatric population boosts the regional market growth. The Middle East & Africa has the least share in the global influenza vaccination market. Presence of the poor economies in the African region restrains the market growth during the forecast period. Majority of the market of the Middle & Africa region is held by the Middle East region.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/influenza-vaccination-market-1621 

 

Primary Cells Market: Segmentation, Industry trends and Development to 2025

 Primary Cells Market is expected to register a CAGR of 8.13% to reach USD 1,233.67 Million till 2025.

Primary human cells are isolated directly from normal human tissue or blood cells via the enzymatic or mechanical method. Primary cells retain their fundamental cellular functions. Hence, their use in cell-based research programs is increasing significantly.

Key factors that drive the primary cells market are the rapid growth in the biotechnology and biopharmaceutical industries, growing cancer research, rising adoption of primary cells over cell lines, increasing demand for monoclonal antibodies, and increasing healthcare expenditure are anticipated to drive the growth of the market during the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/6296 

However, factors such as the high cost of advanced primary cells, and the risk of contamination may hamper the growth of the market. The increasing preference of primary cells in research and development to develop new drug acts as opportunities for the growth of the primary cells market.

Market Dynamics

Growing cancer research across the world demand. Cancer is one of the major causes of death across the globe and is responsible for a large number of deaths. Different pharmaceutical companies and research institutes are involved in developing cancer treatment drugs using cell culture. The increasing prevalence of cancer across the globe is promoting the demand for research activities to develop new drugs. According to the National Cancer Institute in 2018, around 1,735,350 cases of cancer were diagnosed in the US alone.

Additionally, Cancer Research UK reported that in 2018 the new cases of cancer were reported to be 17 million across the world. The increasing number of populations suffering from cancer increases the demand for new research activities to develop new drugs, which ultimately increases the demand for products such as primary cell culture. For instance, the National Cancer Institute conducts different research on cancer biology, cancer genomics, and causes of cancer using primary cell culture. Additionally, there are different major and small manufacturers and suppliers, such as Merck KGaA and PromoCell GmbH, who provide primary cells for cancer research.

Segmentation

The Global Primary Cells Market is segmented into source, Type, and End User. By source, the market has been segmented into hematopoietic cells, skin cells, gastrointestinal cells, liver cells, lung cells, and skeletal and muscle cells.

Based on type, the market has been segmented into human primary cells and animal primary cells. On the basis of end user, the market has been segmented into pharmaceutical and biotechnology companies and research institutes.

Regional Analysis

The Global Primary Cells Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas is expected to hold the largest share of the global primary cells market. The market growth in this region is attributed to the presence of a well-established healthcare system, increasing prevalence of cancer, growing government funding in research, and technological advancements. According to the National Cancer Institute, around 1,685,210 new cases of cancer were diagnosed in the US in 2016. A huge patient pool with cancer is thus driving the growth of the market. Increasing healthcare expenditure by government organizations to provide a better life to the people drives the market growth. For instance, in 2017, the healthcare expenditure in the US was USD 3.5 trillion, and this expenditure increased to USD 3.65 Trillion in 2018.

Europe is expected to account for the second-largest market share during the forecast period. The European market is segmented into Germany, the UK, Italy, Spain, France, and the rest of Europe. Europe held a healthy share in the global primary cells market and is the second-largest market leader after the Americas, owing to the presence of favorable government initiatives & laws, rising prevalence of lifestyle-associated conditions, and the presence of developed economies such as Germany, the UK, and France. According to the Office for National Statistics, the gross domestic expenditure on research and development (R&D) activities was EUR 33.1 billion (USD 35.2 billion) in 2016. The increased spending on research and development activity boosts the market growth in this region.

Asia-Pacific is projected to exhibit the fastest market growth from 2019 to 2025 owing to the increasing per capita health spending, growing geriatric population base, and developing the healthcare sector in China, Japan, India, and Australia. According to the World Bank, the healthcare expenditure in India for the year 2016 was 3.66.% of the total GDP (gross domestic product).

The market in the Middle East and Africa is expected to hold the least market share owing to limited access to treatment facilities. However, the increasing invests by healthcare companies in countries such as Saudi Arabia and the launch of new products will help to strengthen the market growth.

Key Players

The Prominent Players in the Global Primary Cells Market are AllCells (US), American Type Culture Collection (ATCC) ( Virginia), Axol Bioscience Ltd (UK), Cell Biologics, Inc. (Chicago), Lonza Group, AG (Switzerland), Merck KGaA (Germany), PromoCell (UK), STEMCELL Technologies Inc. (Canada), ZenBio, Inc. (Research Triangle Park, NC), Thermo Fisher Scientific Inc. (US), and among others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/primary-cells-market-6296 

 

Nephrectomy Market 2020 Global Trend, Segmentation and Opportunities Forecast To 2025

Nephrectomy Market is expected to register a CAGR of 4.80% and was valued at USD 4,470.17 Million in 2018.

Nephrectomy is a surgical procedure performed to remove the kidney or a part of it. Nephrectomy is of two types, namely, radical nephrectomy in which the entire kidney is removed and partial nephrectomy where a part of the kidney or the diseased tissues is removed as a process of the treatment. Most frequently, a nephrectomy is done to treat kidney cancer or to remove a noncancerous tumor during urological surgery. The demand for nephrectomy is increasing due to the increasing prevalence of kidney cancer and chronic kidney diseases, the rising number of laparoscopic nephrectomy procedures, and increasing awareness about organ (kidney) transplant. These factors are expected to fuel the growth of the global nephrectomy market. However, risks and complications of the nephrectomy surgery and high cost of the procedure are anticipated to hamper the market growth.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5356 

Segment Analysis

The Global Nephrectomy Market has been divided based on procedure, indication, end-user, and region. The market, based on procedure, has been segregated into open nephrectomy, laparoscopic nephrectomy, and robot-assisted laparoscopic surgery. Based on indication, the nephrectomy market has been divided into kidney cancer and another kidney disease. On the basis of end-user, it is bifurcated into hospitals & clinics, surgical centers, and others.

Regional Analysis

The Global Nephrectomy Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Rest of the World. The Americas are likely to hold the largest share of the global nephrectomy market during the assessment period. Increasing prevalence of kidney cancer in the region, high prevalence of chronic kidney diseases, growing development in diagnostics, and well-established players are likely to support the dominance of the Americas during the forecast period. The Europe market established substantial growth in the market due to the increasing incidence and prevalence of cancer in this region. Asia-Pacific is estimated to be the fastest-growing region in the global market due to the increasing R&D funding by developing countries and the development of the healthcare sector in the region. The nephrectomy market in the Rest of the World is expected to witness gradual growth due to the increasing awareness about nephrectomy.

Market Players

MRFR recognizes the following companies as the Key Players in the Global Nephrectomy Market— KARL STORZ SE & Co. KG (Germany)., Olympus Corporation (Japan), Medtronic Plc (Ireland), B. Braun Melsungen AG (Germany), Johnson & Johnson Services Inc. (US), Cook Group (US), CONMED Corporation (US), and XCELLANCE Medical Technologies (India), and Others.

Key Findings of the Study

• The Global Nephrectomy Market was valued at USD 4,470.17 Million in 2018 and is expected to register a CAGR of 4.80% during the assessment period.

• The Americas accounted for the largest share of the global market due to the presence of key market players and the high prevalence of chronic kidney diseases.

• Based on the procedure, the laparoscopic nephrectomy segment accounted for the largest market share of 6% in 2018.

• Based on indication, the other kidney cancer segment is expected to register the fastest growth at a CAGR of 5.01% during the forecast period.

• Based on the end-user, the hospitals & clinics segment accounted for the largest market share of 1% in 2018.

• Some of the players operating in the nephrectomy market are Medtronic, Olympus Corporation, B. Braun Melsungen AG, Johnson & Johnson Services Inc., among others

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/nephrectomy-market-5356 

 

Global Asthma Inhaler Device Market size and forecast, 2020-2025

 Asthma Inhaler Device Market is expected to register a CAGR of 6.42% to reach USD 19,677.54 Million by 2025. Asthma inhaler devices are hand-held, portable devices that are used to deliver medicine to the lungs. Inhaler devices are mainly used to treat or prevent diseases of the airways, including asthma.

Market Dynamics

The prevalence rate of asthma is increasing tremendously. According to the World Health Organization (WHO), in December 2016, an estimated 235 million people had asthma globally. This high prevalence of asthma, growing need for rescue medication, and rising demand for metered-dose inhalers are expected to drive the market growth.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1653  

Segment Analysis

The Global Asthma Inhaler Device Market has been segmented by Type, Mode of Operation, and End User.

The market, based on type, has been bifurcated into the metered-dose inhaler, dry powder inhaler, and soft mist inhaler. The metered-dose inhaler is further sub-segmented into standard pressurized metered-dose inhalers, breath-actuated pressurized metered-dose inhalers, and metered-dose inhaler with a spacer.

Based on the mode of operation, the asthma inhaler device market has been segregated into manually operated inhaler devices and digitally operated inhaler devices.

The global asthma inhaler device market, based on end-user, has been segmented into hospitals & clinics, home care, and others.

Regional Analysis

The Global Asthma Inhaler Device Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas are likely to hold the largest share of the global asthma inhaler device market during the assessment period. The increase in the incidence of asthma, rising demand for metered-dose inhalers, adoption of smart inhalers by the population, and increasing demand for advanced technologies is expected to drive the market growth in the American region.

The Europe market established substantial growth in the market due to the presence of major players such as GlaxoSmithKline PLC, AstraZeneca, and Boehringer Ingelheim, the rising adoption of respiratory inhalers by hospitals and patients in European countries and continuous efforts made by the European Academy of Allergy & Clinical Immunology to increase awareness about asthma.

Asia-Pacific is estimated to be the fastest-growing region in the global market due to the presence of rapidly developing economies such as China, India, and South Korea and the high prevalence of asthma.

The asthma inhaler device market in the Middle East & Africa is expected to witness gradual growth owing to increasing cases of asthma and demand for better treatments in the Middle Eastern countries.

Market Players

MRFR recognizes the following companies as the key players in the Global Asthma Inhaler Device Market— GlaxoSmithKline plc (UK), Koninklijke Philips NV (Netherlands), AstraZeneca (UK), Cipla Inc. (India), Boehringer Ingelheim International GmbH (Germany), Beximco Pharmaceuticals Ltd (Bangladesh), Merck & Co., Inc. (US), Teva Pharmaceutical Industries Ltd (Israel), Chiesi Farmaceutici SpA (Italy), and Medisol Lifescience Pvt. Ltd (India).

Key Findings of the Study

• The Global Asthma Inhaler Device Market is estimated to grow at USD 19,677.54 Million by 2025 at a CAGR of 6.42% during the assessment period

• Americas accounted for the largest share of the global asthma inhaler device market due to the increasing incidence rate of asthma

• Based on type, the metered dose inhalers segment accounted for the largest market share of 42.6% in 2018

• Based on the mode of operation, the manually operated inhaler device segment accounted for the largest market share of 68.1% in 2018

• On the basis of end-user, the hospitals & clinics segment accounted for the largest market share of 52.8% in 2018

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/asthma-inhaler-device-market-1653 

 

Liver Cirrhosis Treatment Market – Revolutionary Trends 2025

 Global Liver Cirrhosis Treatment Market is expected to hold a value of USD 1349.92 Million by 2025 at a CAGR of 5.2%.

Market Synopsis

Liver cirrhosis is a disease in which the liver is severely damaged and scarred, hence leading to liver failure. A lot of research activities are being carried out by major pharmaceutical companies to develop novel drugs for the treatment of liver cirrhosis. Rapidly changing lifestyle is increasing the risk of people suffering from liver cirrhosis. Moreover, people suffering from hepatitis, cystic fibrosis, syphilis, alpha-1 antitrypsin deficiency, alcohol abuse, and other liver diseases are at greater risk of suffering from liver cirrhosis. As of 2015, 887,000 deaths people died suffering from hepatitis B. Most of these deaths were because these patients were suffering from liver cirrhosis and hepatocellular carcinoma (primary liver cancer) along with hepatitis B.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8367 

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to be the largest market owing to the increasing prevalence of liver cirrhosis and high geriatric population. The liver cirrhosis treatment market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European liver cirrhosis treatment market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The liver cirrhosis treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the increasing patient pool of liver cirrhosis and raising awareness about the disease, the market in Asia-Pacific is expected to be the fastest-growing. The liver cirrhosis treatment market in the Middle East & Africa has been divided into the Middle East and Africa.

Segmentation

The global liver cirrhosis treatment market has been segmented based on treatment, and end user.

The global liver cirrhosis treatment market has been segmented, on the basis of treatment, into antibiotics, immunosuppressants, and others. The antibiotics segment is expected to hold the majority share of the market as antibiotics are the most preferred type of prescribed drugs for liver cirrhosis patients due to high risk of infections. The immunosuppressants segment is expected to grow at the fastest CAGR, due to an increasing number of liver transplants. Till October 2017, 147,842 liver transplants have been performed in the Americas. Immunosuppressants are a type of drugs that are prescribed to patients who have undergone liver transplant so that the risk of organ rejection is decreased. Other treatment options include drugs to reduce ammonia levels, antihypertensive drugs, and medications to reduce blood pressure, among others.

The market on the basis of end user has been segmented into hospitals and clinics, research and academic institutes, and others. The hospitals and clinics segment is expected to hold the largest share of the market as they are primary centers of treatment for the patient. Research and academic institutes carry out research activities for the development of new treatment options for liver cirrhosis. Other end users include home care settings and specific centers for the treatment of elderly people.

Key Players

Some of the key players in the global liver cirrhosis treatment market are Pfizer, Inc. (US), Merck & Co., Inc. (Germany), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Takeda Pharmaceutical Company Limited (Japan), Gilead Sciences, Inc. (US), AstraZeneca (UK), Bayer AG (Germany), Sanofi (France), Shionogi Inc. (Japan), and Promethera (Belgium).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/liver-cirrhosis-treatment-market-8367 

 

Digital Healthcare Market Competitive Intelligence Analysis 2020-2025

 Market Research Future (MRFR) expects the Digital Healthcare Market to procure a dashing growth rate of 26.30% between 2019 and 2025 (review period). The market value by the end of 2025 is expected to be USD 3,28,887.8 Million, adds MRFR.

COVID-19 Analysis

The COVID-19 outbreak has left a debilitating impact on the healthcare sector, given the temporary shutdown of manufacturing facilities and weakened demand. Even as the world is trying to curb the spread of SARS-CoV-2, top companies are striving to bolster their supply chains and accelerate their operations to control further losses. Also, the social distancing practice prevalent worldwide has encouraged patients to go for remote healthcare consultation, which bolsters the need for digital healthcare. Healthcare professional are now offering consultation via video conferencing as well as phone calls, in view of the spread of the pandemic. This is more than likely to benefit the digital healthcare market in the years ahead.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/7636 

Segment Analysis

The Global Digital Healthcare Market has been segmented by Technology, Application, Delivery Mode, Components, and End User.

The market, based on technology, has been bifurcated into digital health systems, telehealthcare, mhealth, and healthcare analytics. The digital health systems are further sub-segmented into EHR/EMR and e-prescribing systems. Telehealthcare is further segmented into activity monitoring, remote medication management, LTC monitoring, video consultation. mHealth is further segmented into wearables and mHealth apps. Wearables are furthermore segmented into glucose meters, neurological monitors, sleep apnea monitors, pulse oximeters, BP monitors, and others. mHealth apps is more segmented into fitness apps and medical apps.

Based on application, the digital healthcare market has been segregated into cardiology, diabetes, neurology, sleep apnea, oncology, and others.

Based on delivery mode, the digital healthcare market has been segregated into on-premise and cloud based.

Based on components, the digital healthcare market has been segregated into software, services, and

hardware.

The global digital healthcare market, based on end user, has been segmented into healthcare providers, healthcare payers, pharmaceutical companies, and others.

Regional Analysis

The Global Digital Healthcare Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas is likely to hold the largest share of the global digital healthcare market during the assessment period. The high adoption rate of electronic health records (EHRs) and electronic medical records (EMRs), supportive government initiatives and rise in healthcare funding, and rising pressure to improve the quality of care and reduced healthcare costs likely drive the market growth in the American region.

The Europe market established substantial growth in the market due to the presence of major players such as Allscripts Healthcare, LLC (US), BioTelemetry, Inc. (US), Cerner Corporation (US), Cisco Systems, Inc (US), Koninklijke Philips NV (The Netherlands) and others.

Asia-Pacific is estimated to be the fastest-growing region in the global market due to the presence of rapidly developing economies such as China, India, and South Korea and a rise in research & development centers.

The digital healthcare market in the Middle East & Africa is expected to witness gradual growth owing to increasing government support toward the healthcare IT industry in the Middle East, and rapid technological advancements.

Key Players

MRFR recognizes the following companies as the Key Players in the Global Digital Healthcare Market— Allscripts Healthcare, LLC (US), BioTelemetry, Inc. (US), Cerner Corporation (US), Cisco Systems, Inc (US), Koninklijke Philips NV (The Netherlands), McKesson Corporation (US), General Electric Company (US), AT&T Inc.(US), Athenahealth Inc. (US), EClinicalWorks (US), iHealth Lab Inc. (US), Qualcomm Technologies, Inc.(US).

Key Findings of the Study

• The Global Digital Healthcare Market is estimated to grow at USD 3,28,887.8 Million by 2025 at a CAGR of 26.30% during the assessment period
• The Americas accounted for the largest share of the global digital healthcare market due to the high adoption rate of EHRs and EMRs
• Based on technology, the digital health systems segment accounted for the largest market share of 44.4% in 2018
• Based on application, the cardiology segment accounted for the largest market share of 22.3% in 2018
• On the basis of delivery mode, the software segment accounted for the largest market share of 58.9% in 2018
• On the basis of end user, the healthcare providers segment accounted for the largest market share of 40.2% in 2018

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/digital-healthcare-market-7636